SCHEMBL9898568

SCHEMBL9898568

CC(=O)N[C@@H]1CC[C@H](NC(=O)c2c(C)[nH]c3c(-c4cc(F)ccc4OCC4CC4)ncnc23)C1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK9 P50750 11/20 0.40
CDK1 P06493 5/20 0.40
CDK2 P24941 5/20 0.40
CCNT1 O60563 7/20 0.38
CDK3 Q00526 3/20 0.38
CDK5 Q00535 3/20 0.38
GSK3A P49840 2/20 0.38
GSK3B P49841 2/20 0.38
CCNB1 P14635 2/20 0.38
CCNE1 P24864 2/20 0.38
CCNA1 P78396 2/20 0.38
CDK5R1 Q15078 2/20 0.38
CASP3 P42574 1/20 0.37
CASP7 P55210 1/20 0.37
BRD4 O60885 1/20 0.36
GRIN1 Q05586 2/20 0.36
GRIN2B Q13224 2/20 0.36
CDK4 P11802 1/20 0.34
ACACB O00763 1/20 0.34
ABL1 P00519 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9898566 1.00 CDK9 (0.40) CDK9CDK1CDK2CCNT1CDK3
SCHEMBL9898675 1.00 CDK9 (0.40) CDK9CDK1CDK2CCNT1CDK3
SCHEMBL9896182 0.97 CDK9 (0.40) CDK9CDK1CDK2CCNT1CDK3
SCHEMBL1439033 0.97 CDK9 (0.40) CDK9CDK1CDK2CCNT1CDK3
SCHEMBL1439031 0.97 CDK9 (0.40) CDK9CDK1CDK2CCNT1CDK3
SCHEMBL9897391 0.93 GRIN1 (0.39) CDK9CDK1CDK2CCNT1BRD4
SCHEMBL9897901 0.93 GRIN1 (0.39) CDK9CDK1CDK2CCNT1BRD4
SCHEMBL9897393 0.93 GRIN1 (0.39) CDK9CDK1CDK2CCNT1BRD4
SCHEMBL9896692 0.93 CDK9 (0.36) CDK9CDK1CDK2CCNT1CDK3
SCHEMBL9897223 0.93 CDK9 (0.36) CDK9CDK1CDK2CCNT1CDK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9376442-B2 Methylpyrrolopyrimidinecarboxamides TAKEDA GMBH (DE) 2016-06-28 US disclosed
US-20150073001-A1 METHYLPYRROLOPYRIMIDINECARBOXAMIDES ASTRAZENECA AB (SE) 2015-03-12 US disclosed
US-8927557-B2 Methylpyrrolopyrimidinecarboxamides TAKEDA GMBH (DE) 2015-01-06 US disclosed
EP-2470536-B1 Methylpyrrolopyrimidinecarboxamides TAKEDA GMBH (DE) 2014-11-12 EP disclosed
US-20120149721-A1 METHYLPYRROLOPYRIMIDINECARBOXAMIDES NYCOMED GMBH (DE) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149721-A1 METHYLPYRROLOPYRIMIDINECARBOXAMIDES PDE5A, PDE12, PDE4A CDK9 641/4885CDK1 945/4885CDK2 298/4885
US-20150073001-A1 METHYLPYRROLOPYRIMIDINECARBOXAMIDES PDE12, PDE5A, PDE4A CDK9 808/4885CDK1 1342/4885CDK2 479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.